The Laboratory Corporation of America Holdings or LabCorp has embarked on several impressive ventures recently, marking a substantial period of growth and development for the company. They have secured a new $750 million term loan and expanded their collaboration with Illumina Precision Oncology Alliance. Despite some institutions opting to sell their shares, others like Gotham Asset Management and Dakota Wealth Management have increased their own. Significant buying activity is also seen from public figures like Rep. April McClain Delaney and institutions like Victory Capital Management. There has been increasing belief in the company’s financial growth with Morgan Stanley boosting the price target of LH shares to $283 and affirming an ‘Overweight’ rating. Future undertakings include an AI Pathology rollout with PathAI and a contract research slowdown for an oncology push. LabCorp has also managed to surpass Q4 earnings estimates while continuing to announce regular dividends. The company has made strategic investments such as expanding collaboration with PathAI to deploy an FDA-cleared digital pathology platform nationwide. The company has also involved itself in diversifying its executive board with the appointment of Victor Bulto.
Laboratory Corporation of America Holdings LH News Analytics from Wed, 05 Nov 2014 08:00:00 GMT to Fri, 20 Mar 2026 21:37:35 GMT - Rating 8 - Innovation 7 - Information 8 - Rumor 5
